The Effect of Intravenous Lidocaine on Normal Sensation and Pain in Healthy Volunteers

The University of Alabama at Birmingham

Status: Completed

Conditions: Pain

Treatments: Drug: Lidocaine

Study type: Interventional

Funder types: Other

Identifiers

NCT00657358

F061204013

Details and patient eligibility

About

The purpose of this study is to study if lidocaine, given intravenously, reduces pain.

Full description

Clinicians use lidocaine intravenously in a fashion that suggests that it might have analgesic effects. Therefore, we test the hypothesis that lidocaine reduces pain intensity in response to experimental pain.

Enrollment: 22 patients

Sex: All

Ages: 19+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy Adult Volunteers, age >19 years

Exclusion criteria

• History of Substance Abuse
• Coronary Artery Disease (CAD): unstable
• Congestive Heart Failure (CHF): unstable
• Heart Arrhythmia: symptomatic
• Chronic Obstructive Pulmonary Disease (COPD)
• Lidocaine Allergy
• Diagnostic and Statistical Manual of Mental Disorders (Rev IV): Axis I: Common Axis I disorders include depression, anxiety disorders,bipolar disorder, ADHD, and schizophrenia. Axis II: borderline personality disorder, schizotypal personality disorder, antisocial personality disorder, and mild mental retardation.
• Presence of Contraindications for MRI
• Presence of electronically, magnetically, and mechanically activated implants
• Electronically, magnetically, and mechanically activated implants
• Ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators
• Cardiac pacemakers
• Metallic splinters in the eye
• Ferromagnetic haemostatic clips in the central nervous system (CNS)
• Claustrophobia
• Pregnancy

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

22 participants in 1 patient group

Lidocaine

Experimental group

Description:

Lidocaine 2% (2mg/ml) was administered via a computer assisted infusion to achieve a target plasma concentration of 2 mcg/ml; infused within 20 minutes.

Treatment:

Drug: Lidocaine